• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症和血液学标志物作为 COVID-19 感染严重结局的预测因子:系统评价和荟萃分析。

Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis.

机构信息

Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, Banten, Indonesia.

Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, Banten, Indonesia.

出版信息

Am J Emerg Med. 2021 Mar;41:110-119. doi: 10.1016/j.ajem.2020.12.076. Epub 2020 Dec 30.

DOI:10.1016/j.ajem.2020.12.076
PMID:33418211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7831442/
Abstract

BACKGROUND

Laboratory testing is commonly performed in patients with COVID-19. Each of the laboratory parameters has potential value for risk stratification and prediction of COVID-19 outcomes. This systematic review and meta-analysis aimed to evaluate the difference between these parameters in severe and nonsevere disease and to provide the optimal cutoff value for predicting severe disease.

METHOD

We performed a systematic literature search through electronic databases. The variables of interest were serum procalcitonin, albumin, C-reactive protein (CRP), D-dimer, and lactate dehydrogenase (LDH) levels in each group of severity outcomes from COVID-19.

RESULTS

There were a total of 4848 patients from 23 studies. Our meta-analysis suggest that patients with severe COVID-19 infections have higher procalcitonin, (mean difference 0.07; 95% CI 0.05-0.10; p < 0.00001), CRP (mean difference 36.88; 95% CI 29.10-44.65; p < 0.00001), D-Dimer (mean difference 0.43; 95% CI 0.31-0.56; p < 0.00001), and LDH (mean difference 102.79; 95% CI 79.10-126.49; p < 0.00001) but lower levels of albumin (mean difference -4.58; 95% CI -5.76 to -3.39; p < 0.00001) than those with nonsevere COVID-19 infections. The cutoff values for the parameters were 0.065 ng/mL for procalcitonin, 38.85 g/L for albumin, 33.55 mg/L for CRP, 0.635 μ/L for D-dimer, and 263.5 U/L for LDH, each with high sensitivity and specificity.

CONCLUSION

This meta-analysis suggests elevated procalcitonin, CRP, D-dimer, and LDH and decreased albumin can be used for predicting severe outcomes in COVID-19.

摘要

背景

在 COVID-19 患者中,实验室检测通常是常规进行的。每个实验室参数对于 COVID-19 结果的风险分层和预测都具有潜在价值。本系统回顾和荟萃分析旨在评估这些参数在重症和非重症疾病中的差异,并为预测重症疾病提供最佳截断值。

方法

我们通过电子数据库进行了系统文献检索。感兴趣的变量是 COVID-19 各组严重程度结局的血清降钙素原、白蛋白、C 反应蛋白(CRP)、D-二聚体和乳酸脱氢酶(LDH)水平。

结果

共有来自 23 项研究的 4848 名患者。我们的荟萃分析表明,重症 COVID-19 感染患者的降钙素原(均数差 0.07;95%置信区间 0.05-0.10;p<0.00001)、CRP(均数差 36.88;95%置信区间 29.10-44.65;p<0.00001)、D-二聚体(均数差 0.43;95%置信区间 0.31-0.56;p<0.00001)和 LDH(均数差 102.79;95%置信区间 79.10-126.49;p<0.00001)水平较高,而白蛋白(均数差 -4.58;95%置信区间 -5.76 至 -3.39;p<0.00001)水平较低。这些参数的截断值分别为降钙素原 0.065ng/ml、白蛋白 38.85g/L、CRP 33.55mg/L、D-二聚体 0.635μ/L 和 LDH 263.5U/L,每个参数的灵敏度和特异性都较高。

结论

本荟萃分析表明,升高的降钙素原、CRP、D-二聚体和 LDH 以及降低的白蛋白可用于预测 COVID-19 的严重结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/3afaba5203c1/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/559ad2722a43/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/951b576ddafd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/130bb3070f5e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/3afaba5203c1/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/559ad2722a43/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/951b576ddafd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/130bb3070f5e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0545/7831442/3afaba5203c1/gr4_lrg.jpg

相似文献

1
Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis.炎症和血液学标志物作为 COVID-19 感染严重结局的预测因子:系统评价和荟萃分析。
Am J Emerg Med. 2021 Mar;41:110-119. doi: 10.1016/j.ajem.2020.12.076. Epub 2020 Dec 30.
2
C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.C 反应蛋白、降钙素原、D-二聚体和铁蛋白在严重 2019 冠状病毒病中的meta 分析。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175. doi: 10.1177/1753466620937175.
3
Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19.中性粒细胞与淋巴细胞比值,新冠肺炎患者疾病严重程度评估的关键预测指标。
Int J Lab Hematol. 2021 Apr;43(2):329-335. doi: 10.1111/ijlh.13374. Epub 2020 Oct 25.
4
CRP, SAA, LDH, and DD predict poor prognosis of coronavirus disease (COVID-19): a meta-analysis from 7739 patients.CRP、SAA、LDH 和 DD 预测冠状病毒病 (COVID-19) 预后不良:来自 7739 例患者的荟萃分析。
Scand J Clin Lab Invest. 2021 Dec;81(8):679-686. doi: 10.1080/00365513.2021.2000635. Epub 2021 Nov 11.
5
The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis.与 COVID-19 相关的儿童(MIS-C)和青少年多系统炎症综合征的炎症标志物:一项荟萃分析。
J Med Virol. 2021 Jul;93(7):4358-4369. doi: 10.1002/jmv.26951. Epub 2021 Apr 1.
6
Risk factors of severe cases with COVID-19: a meta-analysis.COVID-19 重症病例的风险因素:荟萃分析。
Epidemiol Infect. 2020 Aug 12;148:e175. doi: 10.1017/S095026882000179X.
7
A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients.对与COVID-19患者病情加重相关的临床和实验室参数的系统评价。
Diabetes Metab Syndr. 2021 Mar-Apr;15(2):535-541. doi: 10.1016/j.dsx.2021.02.020. Epub 2021 Feb 20.
8
Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.炎症生物标志物在 COVID-19 感染患者中的应用:巴林经验。
Biomark Med. 2021 Jun;15(8):541-549. doi: 10.2217/bmm-2020-0422. Epub 2021 May 14.
9
Identifying the Probable Etiology of Acute Undifferentiated Fever through Inflammatory Markers.通过炎症标志物识别急性未分化发热的可能病因。
J Assoc Physicians India. 2024 May;72(5):13-16. doi: 10.59556/japi.72.0523.
10
The value of clinical parameters in predicting the severity of COVID-19.临床参数在预测 COVID-19 严重程度中的价值。
J Med Virol. 2020 Oct;92(10):2188-2192. doi: 10.1002/jmv.26031. Epub 2020 Jun 2.

引用本文的文献

1
The Role of Serial Monitoring of Laboratory Parameters in Determining the Need for Intensive Care in Severe COVID-19: A Single-Center Retrospective Study.实验室指标的连续监测在确定重症 COVID-19 患者重症监护需求中的作用:一项单中心回顾性研究
Infect Dis Clin Microbiol. 2025 Jun 26;7(2):133-142. doi: 10.36519/idcm.2025.508. eCollection 2025 Jun.
2
Assessment of the Abnormalities in Chest Computed Tomography and Pulmonary Function Test in Convalescents Six Months After COVID-19.新型冠状病毒肺炎康复者六个月后胸部计算机断层扫描及肺功能测试异常情况评估
Medicina (Kaunas). 2025 Apr 29;61(5):823. doi: 10.3390/medicina61050823.
3

本文引用的文献

1
Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study.中国浙江 COVID-19 患者病情恶化的危险因素和临床特征:一项单中心回顾性研究。
BMC Infect Dis. 2020 Dec 10;20(1):943. doi: 10.1186/s12879-020-05682-4.
2
Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection.托珠单抗治疗与降低 2019 冠状病毒病感染的生物标志物有关。
J Med Virol. 2021 Mar;93(3):1832-1836. doi: 10.1002/jmv.26698. Epub 2020 Dec 17.
3
Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait.
Role of Procalcitonin as a Prognostic Biomarker in Hospitalized COVID-19 Patients: A Comparative Analysis.
降钙素原作为住院COVID-19患者预后生物标志物的作用:一项比较分析。
Biomark Insights. 2025 May 15;20:11772719241296624. doi: 10.1177/11772719241296624. eCollection 2025.
4
Assessment of COVID-19 patients' outcome based on clinical profile, laboratory parameters, and clinical management: A retrospective observational study.基于临床特征、实验室参数和临床管理评估COVID-19患者的预后:一项回顾性观察研究。
J Family Med Prim Care. 2024 Oct;13(10):4678-4683. doi: 10.4103/jfmpc.jfmpc_787_24. Epub 2024 Oct 18.
5
Micronutrients, Vitamin D, and Inflammatory Biomarkers in COVID-19: A Systematic Review and Meta-analysis of Causal Inference Studies.2019冠状病毒病中的微量营养素、维生素D与炎症生物标志物:因果推断研究的系统评价与荟萃分析
Nutr Rev. 2025 Jul 1;83(7):e1383-e1405. doi: 10.1093/nutrit/nuae152.
6
DNA Damage in Moderate and Severe COVID-19 Cases: Relation to Demographic, Clinical, and Laboratory Parameters.中度和重度 COVID-19 病例中的 DNA 损伤:与人口统计学、临床和实验室参数的关系。
Int J Mol Sci. 2024 Sep 24;25(19):10293. doi: 10.3390/ijms251910293.
7
Severe COVID-19 infection: An institutional review and literature overview.严重 COVID-19 感染:机构审查和文献综述。
PLoS One. 2024 Aug 20;19(8):e0304960. doi: 10.1371/journal.pone.0304960. eCollection 2024.
8
Longitudinal importance of the soluble receptor for advanced glycation end-products in nonintubated hospitalized patients with COVID-19 pneumonia.非插管住院 COVID-19 肺炎患者中可溶性晚期糖基化终产物受体的纵向重要性。
Am J Physiol Lung Cell Mol Physiol. 2024 Nov 1;327(5):L607-L614. doi: 10.1152/ajplung.00350.2023. Epub 2024 Jul 30.
9
Predictive Value and Diagnostic Potential of IL-10, IL-17A, IL1-β, IL-6, CXCL, and MCP for Severe COVID-19 and COVID-19 Mortality.IL-10、IL-17A、IL1-β、IL-6、CXCL和MCP对重症COVID-19及COVID-19死亡的预测价值和诊断潜力
Biomedicines. 2024 Jul 10;12(7):1532. doi: 10.3390/biomedicines12071532.
10
Combined coagulation and inflammation markers as predictors of venous thrombo-embolism and death in COVID-19.联合凝血和炎症标志物作为COVID-19患者静脉血栓栓塞和死亡的预测指标
Front Med (Lausanne). 2024 Jun 10;11:1399335. doi: 10.3389/fmed.2024.1399335. eCollection 2024.
科威特 2019 年冠状病毒病(COVID-19)患者的临床特征。
PLoS One. 2020 Nov 20;15(11):e0242768. doi: 10.1371/journal.pone.0242768. eCollection 2020.
4
Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection.痴呆是2019冠状病毒病(COVID-19)感染导致死亡结果的一个预测因素。
Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):393-395. doi: 10.1007/s00406-020-01205-z. Epub 2020 Oct 26.
5
Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: a multicentre retrospective study.中国武汉以外的陕西省输入性和第二代 2019 年冠状病毒病(COVID-19)病例的临床特征:一项多中心回顾性研究。
Epidemiol Infect. 2020 Sep 30;148:e238. doi: 10.1017/S0950268820002332.
6
Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.他汀类药物治疗并未改善 2019 冠状病毒病(COVID-19)感染患者的住院结局。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615. doi: 10.1016/j.dsx.2020.08.023. Epub 2020 Aug 26.
7
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection.使用二甲双胍与降低2019冠状病毒病(COVID-19)感染的死亡率相关。
Obes Med. 2020 Sep;19:100290. doi: 10.1016/j.obmed.2020.100290. Epub 2020 Aug 18.
8
Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait.科威特首批连续确诊的1096例新冠肺炎患者的特征、风险因素及预后
EClinicalMedicine. 2020 Jul 4;24:100448. doi: 10.1016/j.eclinm.2020.100448. eCollection 2020 Jul.
9
Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection.甲状腺疾病与2019冠状病毒病(COVID-19)严重感染相关。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1429-1430. doi: 10.1016/j.dsx.2020.07.044. Epub 2020 Jul 29.
10
Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis.乳酸脱氢酶水平可预测 2019 冠状病毒病(COVID-19)的严重程度和死亡率:一项汇总分析。
Am J Emerg Med. 2020 Sep;38(9):1722-1726. doi: 10.1016/j.ajem.2020.05.073. Epub 2020 May 27.